1 September 2026A national framework with the NHS Genomic Medicine Service brings methylation-based CNS tumour classification to genomic laboratory services across England, free of charge for all paediatric patients for three years.
1 June 2026Prof. Dr. Dr. med. Felix Sahm joins as Chief Medical Advisor, guiding clinical and medical strategy as the company expands its precision diagnostics portfolio.
8 July 2025A substantial update to the sarcoma tumour classifier, extending precision methylation-based classification beyond tumours of the central nervous system.
6 May 2025CMS has released a preliminary Medicare reimbursement rate for the CPT® code covering the Epignostix CNS Tumor Methylation Classifier.
22 January 2025The CNS and sarcoma tumour classifiers go live, extending methylation-based classification from the flagship CNS indication to further applications.
16 July 2024Helge Lubenow becomes Chief Executive Officer, succeeding founder David Jones, who continues with the company as Chief Scientific Officer.
2 July 2024A €4.3M seed round led by CARMA FUND I, with High-Tech Gründerfonds, LBBW Venture Capital and Start-up BW, to accelerate brain tumour classification.
